Skip to main content
. 2017 Dec 6;36:177. doi: 10.1186/s13046-017-0647-5

Table 2.

Combination index (CI) and dose reduction index (DRI) values for VPA and 5′-DFUR combination treatment

Cell lines aCI50 ± SD
VPA + 5′-DFUR
aCI75 ± SD
VPA + 5′-DFUR
aCI90 ± SD
VPA + 5′-DFUR
bDRI at IC50 ± SD
VPA 5′-DFUR
HT29 0.87 ± 0.17 0.75 ± 0.07 0.75 ± 0.078 1.65 ± 0.35 2.56 ± 0.62
SW620 0.81 ± 0.10 0.83 ± 0.16 0.74 ± 0.24 2.91 ± 1.49 1.90 ± 0.40
HCT-116 0.87 ± 0.02 0.86 ± 0.04 0.77 ± 0.03 1.85 ± 0.28 2.44 ± 0.22
HCT-116 p53−/− 1.24 ± 0.15 1.15 ± 0.03 1.15 ± 0.17 1.43 ± 0.24 1.75 ± 0.33

aCI values (mean ± SD from at least three separate experiments performed in quadruplicates) computed at 50, 75 and 90% of cell kill (CI50, CI75and CI90, respectively) according by CalcuSyn software after 96 h of treatment. Combinations were considered strongly synergistic when CIs were below 0.9. bDRI values (mean ± SD . from at least three separate experiments performed in quadruplicates) represents the order of magnitude (fold) of dose reduction obtained for IC50 (DRI50) in combination setting compared with each drug alone